A patient with acquired hemophilia A induced by clopidogrel.
- Author:
Hye Won HWANG
1
;
Jee Hyun KONG
;
Dong Wook YU
;
Woo Taek KIM
;
Hyun Soo KIM
;
Chong In LEE
Author Information
- Publication Type:Case Report
- Keywords: Acquired hemophilia; Clopidogrel; Factor VIII; FVIII autoantibodies
- MeSH: Aged; Autoantibodies; Factor VIII; Follow-Up Studies; Hemophilia A; Hemorrhage; Humans; Infarction; Partial Thromboplastin Time; Plasma; Platelet Count; Ticlopidine
- From:Korean Journal of Hematology 2012;47(1):80-82
- CountryRepublic of Korea
- Language:English
- Abstract: Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Treatment with clopidogrel is a cause of AHA, but its clinical course is unknown. Recently, we treated a 65-year-old man who was hospitalized for cerebellar infarction and had a prolonged activated partial thromboplastin time (aPTT) with soft tissue oozing after 3 weeks of clopidogrel use. We terminated clopidogrel administration and transfused the patient with fresh frozen plasma. However, the aPTT increased up to 98.8 seconds, and the FVIII and FVIII inhibitor levels were <1% and 5.4 Bethesda units/mL, respectively. Clopidogrel-associated AHA was considered, and we began steroid treatment. Two months later, FVIII, FVIII inhibitor, and aPTT values were normalized. No further bleeding or aPTT prolongation has been reported during the 2-year follow-up period. AHA should be considered in patients taking clopidogrel and experiencing bleeding, unless the platelet count and coagulation screen are normal.
